UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | January 4, 2013 |
Endocyte, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 001-35050 | 35-1969-140 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana | | 47906 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 765-463-7175 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| | | ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS | |
On January 4, 2013, the Board of Directors (the “Board”) of Endocyte, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, elected Lesley Russell, M.B.Ch.B., to the Board, with a term to expire at the Company’s 2014 annual meeting of stockholders. The appointment fills a newly created directorship position on the Board. The Company expects that Dr. Russell will be appointed to the Audit Committee. There are no arrangements or understandings between Dr. Russell and any other persons pursuant to which Dr. Russell was appointed a director of the Company.
As a non-employee director, Dr. Russell will participate in the non-employee director compensation arrangements described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 13, 2012.
A copy of the Company’s press release announcing the appointment of Dr. Russell to the Board is attached hereto as Exhibit 99.1, and the information set forth therein is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| | | | | |
| Exhibit No. | | Description |
| | | | | |
| | 99.1 | | | Press release dated January 8, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Endocyte, Inc. |
| | | | | |
| January 8, 2013 | | By: | | /s/ Michael A. Sherman
|
| | | | |
|
| | | | | Name: Michael A. Sherman |
| | | | | Title: Chief Financial Officer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press release dated Janaury 8, 2013 |
